Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?

The article compares Abbott Laboratories and UnitedHealth Group as healthcare investment options. Abbott, with $44.3B in revenue and a conservative 0.3x debt-to-equity ratio, focuses on medical devices, diagnostics, and pharmaceuticals, with planned growth from the Exact Sciences acquisition and a nutrition business spin-off. UnitedHealth, with $447.6B in revenue but higher leverage at 0.8x debt-to-equity, dominates insurance and healthcare services but faces government policy risks and reputational challenges. The author recommends Abbott for its innovation focus and lower exposure to healthcare cost-control initiatives.

10/24/2026, 1:11 PM • The Motley Fool

UnitedHealth: 3 Key Takeaways for Long-Term Investors

UnitedHealth reported Q3 2026 earnings with strong operational momentum driven by AI integration and enterprise reforms. The company reiterated its 13-16% long-term growth target, highlighting AI-enabled workflow improvements, a 30% reduction in prior authorizations, and strong commercial client retention heading into 2027. Q3 revenue reached $113 billion with adjusted EPS of $4.69.

10/17/2026, 2:47 PM • The Motley Fool

Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading

Major stock indexes traded mixed on October 13, 2026, as bank earnings kicked off the season with varied results and semiconductor stocks faced significant selling pressure. The S&P 500 fell 0.25%, the Nasdaq dropped 0.37%, and the Dow declined 0.18%. Goldman Sachs gained on strong earnings, while Wells Fargo and Johnson & Johnson declined on disappointing results. Semiconductor stocks, particularly Micron Technology, slid over 5% amid intensifying global competition and Chinese chip innovations.

10/13/2026, 12:14 PM • The Motley Fool

UnitedHealth Reports on Oct. 13. Here's the 1 Number I'm Watching.

UnitedHealth Group will report Q3 earnings on October 13. The key metric to watch is the medical care ratio (MCR), which measures the percentage of insurance premiums paid out for claims. A lower MCR improves profitability. UnitedHealth successfully reduced its MCR to 86.7% in Q2 from 89.4% a year earlier, driven by benefit design, pricing discipline, and member mix adjustments. Investors will closely monitor whether the company can maintain or further reduce this critical ratio.

10/03/2026, 7:30 AM • The Motley Fool

Warren Buffett's Record: $1,000 Became About $61 Million. Can Greg Abel Keep Compounding It?

Warren Buffett stepped down as Berkshire Hathaway chairman in September 2026, ending an era of exceptional returns (6,099,294% since 1965). New CEO Greg Abel faces the challenge of maintaining growth, but Berkshire's massive $1.1 trillion size makes repeating historical 19.7% annual returns virtually impossible. The company has underperformed the S&P 500 over the past decade and is sitting on $365.6 billion in cash while making strategic portfolio shifts.

09/30/2026, 7:30 PM • The Motley Fool

Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies

Hatteras Venture Partners appointed Sir Andrew Witty as Chairman and Dr. Ned Sharpless as Managing Director of Hatteras Discovery Innovation. The firm announced the first closing of Hatteras Opportunity Fund II targeting $100 million, bringing total capital under management to over $1 billion. The new Discovery strategy aims to replicate the success of the original 2012 initiative that seeded 11 companies and contributed to two FDA-approved medicines.

09/30/2026, 7:00 AM • GlobeNewswire

Reuters Momentum AI Austin Day 1: A New Way to Measure Whether AI Is Actually Paying Off

Enterprise AI is shifting from experimentation to demonstrating measurable ROI. Companies like FedEx ($3B in cost reductions), Mars (20% top-line growth), and Indeed (70% of matches from AI) are scaling AI beyond pilots, but success requires organizational redesign, clear ownership, and human oversight. Leaders warn that AI can amplify existing organizational weaknesses and autonomous agents need defined spending limits and accountability measures.

09/24/2026, 8:30 PM • GlobeNewswire

Europe Clinical Data Analytics Market Outlook 2026-2033 | AI, Cloud Deployment and Data-Driven Healthcare Adoption Accelerate Across the Region

Europe's clinical data analytics market is projected to reach USD 105.6 billion by 2031, growing at a 27% CAGR through 2033. Growth is driven by healthcare digitalization, AI adoption, cloud deployment, and regulatory initiatives like the European Health Data Space. Software and cloud-based solutions lead the market, with healthcare providers and payers increasingly investing in analytics for improved patient outcomes and operational efficiency.

09/24/2026, 4:57 AM • GlobeNewswire

NASP Announces 2026 Industry Award Winners at Record-Breaking inSPire2026 Conference

The National Association of Specialty Pharmacy (NASP) recognized industry leaders and organizations at its annual conference in National Harbor, Maryland. Award recipients included Optum Specialty Pharmacy (Specialty Pharmacy of the Year), Van Chau from UC Davis Health (Pharmacist of the Year), and Pfizer (Manufacturer of the Year), among others. The record-breaking conference attracted over 2,400 specialty pharmacy professionals.

09/23/2026, 11:00 AM • GlobeNewswire

Global Value-Based Healthcare Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

The value-based healthcare market is experiencing robust growth, projected to reach USD 62 billion by 2034 from USD 16.5 billion in 2025, with a CAGR of ~16%. The shift from fee-for-service to outcome-based payment models is driven by rising healthcare costs, chronic disease burden, and government reimbursement reforms. North America dominates with 72% market share, while Asia-Pacific is expected to record the fastest growth. Key players include Optum, Humana, Evolent Health, Agilon Health, and Privia Health.

09/16/2026, 1:00 PM • GlobeNewswire

Telepsychiatry Market Size to Surge to USD 70.95 Billion by 2035 at a CAGR of 20.81% - SNS Insider

The global telepsychiatry market is projected to grow from USD 10.71 billion in 2025 to USD 70.95 billion by 2035 at a CAGR of 20.81%, driven by psychiatrist shortages, reimbursement reforms, and increased adoption of virtual mental healthcare. North America leads with 32% market share, while Asia Pacific shows the fastest growth. Key trends include AI-driven patient matching, employer-sponsored programs, and integration with primary care.

09/14/2026, 8:30 PM • GlobeNewswire

Enterprise Imaging Solutions Market Set to Hit USD 6.69 Billion by 2035, Growing at a CAGR of 11.18% - SNS Insider

The Enterprise Imaging Solutions Market is projected to grow from USD 2.32 billion in 2025 to USD 6.69 billion by 2035, with a CAGR of 11.18%. Growth is driven by cloud-native platforms, AI-driven workflows, and vendor consolidation. North America leads with 44% market share, while Asia-Pacific shows the fastest growth at 15% CAGR. Software remains the largest component at 58% share, with cloud deployment and services as the fastest-growing segments.

09/10/2026, 8:30 PM • GlobeNewswire

1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive passive income potential. The ETF has delivered 29% total returns year-to-date and is particularly suitable for tax-advantaged accounts like Roth IRAs.

09/08/2026, 2:37 PM • The Motley Fool

UnitedHealth Group Stock Is Up 39.4% in the Last 6 Months. How High Can It Go?

UnitedHealth Group (UNH) surged 39.4% over six months, driven by strong Q1 earnings and investor confidence in the company's turnaround efforts, including a $3 billion AI investment. However, the stock has pulled back since July due to concerns about rising healthcare costs from GLP-1 drugs and independent dispute resolutions. Trading at 18x estimated 2027 earnings, analysts remain bullish, viewing recent volatility as a potential buying opportunity if management's AI-driven strategy delivers expected mid-to-high teens earnings growth.

09/08/2026, 9:05 AM • The Motley Fool

Billionaire David Tepper Sold Every Single Share of UnitedHealth in Q2. Here's Whether He Made a Costly Mistake.

Billionaire hedge fund manager David Tepper sold all 90,000 shares of UnitedHealth in Q2 to concentrate on AI investments. While medical cost pressures from GLP-1 drugs and inflation are real concerns, the article argues Tepper may have made a mistake, as UnitedHealth is actively managing costs through AI automation, workflow improvements, and strategic GLP-1 coverage policies. The company's operating margins improved and earnings growth remains strong, suggesting it's adapting well to healthcare industry changes.

08/26/2026, 6:30 AM • The Motley Fool